Nestin
NESproteinNestin marks neovessel formation in the infarction zone, indicating cardiomyocyte injury and myocardial remodeling.
Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencelow
RationaleNeovascularization marker; reflects post-MI tissue remodeling and collateral growth.
Also acts inEndothelial activation/erosion
Druggability
DruggableNo
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableNo
EnsemblENSG00000132688
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I52
C — confounder / Type-II88
A — assay feasibility68
E — evidence strength32
T1DI (composite)7
Specificity differential (R−C)-35.7
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Nestin expression by newly formed human blood vessels.Stem cells and development · 2004 · PMID 15684833 · doi